kezar life sciences news

Kezar Life Sciences Inc. 3 brokers have issued 12-month price targets for Kezar Life Sciences shares.

Kezar Life Sciences Crunchbase Company Profile Funding

SOUTH SAN FRANCISCO Calif.

. Nov 15 2021 405pm EST. Kezar Life Sciences KZR-616 an Orphan Drug in US. KZR a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders today reported financial results for the first quarter ended March 31 2022 and provided a business update.

This suggests a possible upside of 1998 from the stocks current price. Possible turnaround for Kezar Life Sciences Inc. NASDAQKZR insiders still down US17k after a US13m shopping spree.

KZR a clinical-stage biotechnology company discovering and developing breakthrough treatments. Kezar Life Sciences Inc. The shares were bought at an average cost.

Some of the losses seen. Kezar Life Sciences press release KZR. Possible turnaround for Kezar Life Sciences Inc.

Kezar Life Sciences Inc KZR shares closed today at 07 below its 52 week high of 1634 giving the company a market cap of 775M. The stock is currently up 2023 year-to-date up 1833 over the past 12 months and down 111 over the past five years. 1 day agoIn other news Director Franklin M.

-- Business Wire Kezar Life Sciences Inc. The Company tendered his resignation from the Board effective immediately. Kezar Life Sciences Inc.

2 days agoResignation of Director. Kezar Life Sciences climbs after over 1 million insider purchase. Maintained a Buy rating on the stock and raised its price target from 20 to 22.

Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis. Kezar Life Sciences Inc NASDAQ. In connection with his resignation from the Board Dr.

I want to thank my colleagues at Kezar for their excellent. Is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San. The stock was bought at an average cost of 1674 per share.

KZR shares are trading lower by 3823 at 761 after the company announced top-line results from its PRESIDIO Phase 2. Their forecasts range from 1400 to 2200. SOUTH SAN FRANCISCO Calif May 12 2022 -- BUSINESS WIRE -- Kezar Life Sciences Inc.

Berger bought 60000 shares of Kezar Life Sciences stock in a transaction dated Friday March 18th. KZR shares are trading higher by 50 at 1608 after HC Wainwright Co. On May 11 2022 Jean-Pierre Sommadossi PhD Chairman of the Board of Directors the Board of Kezar Life Sciences Inc.

The company is pioneering first-in-class small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single powerful targets. BioMarin FDA Decision Tapering Earnings News. Berger purchased 60000 shares of the businesss stock in a transaction on Friday March 18th.

4000 Shoreline Court Suite 300 South San Francisco CA 94080 T. Kezar Life Sciences Inc. Recent News View All News.

Kezar Life Sciences Inc NASDAQ. KZR a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders today reported financial results for the first quarter ended March 31 2022 and provided a business update. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

For autoimmune inflammatory disorders SA News Fri Oct. On average they anticipate Kezar Life Sciences stock price to reach 1667 in the next year. Kezar Life Sciences Inc.

Q1 GAAP EPS of -026 beats by 002Cash cash equivalents and marketable securities totaled. Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Sommadossi also resigned from all committees of the Board on.

1 day agoIn other Kezar Life Sciences news Director Franklin M. Kezar Life Sciences rises 66 on phase 2 data for lupus candidate Benzinga 167d The Week Ahead In Biotech Nov. Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635c4 May 5 2022 430pm EDT.

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. 23 2020 Encouraging lupus data lifts Kezar Life Sciences up 9 after hours. The company is pioneering first-in-class small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single powerful targets.

NASDAQKZR insiders still down US17k after a US13m shopping spree.

Kazar Life Sciences Stock Soars 73 On Results Of Lupus Trial San Francisco Business Times